Tokyo Tape
Sign in
← Carna Biosciences

Quarterly report · Q3

4572.TEDINET S100PEWN
Period2022-01-01 → 2022-09-30
Filed2022-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥1.1bn2022-01-01 → 2022-09-30Cons.Net sales
Revenue¥2.0bn2021-01-01 → 2021-12-31Cons.Net sales (5-year summary)
Revenue¥637m2021-01-01 → 2021-09-30Cons.Net sales
Operating income−¥754m2022-01-01 → 2022-09-30Cons.Operating income
Operating income−¥1.2bn2021-01-01 → 2021-09-30Cons.Operating income
Ordinary income−¥736m2022-01-01 → 2022-09-30Cons.Ordinary income
Ordinary income−¥523m2021-01-01 → 2021-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥1.2bn2021-01-01 → 2021-09-30Cons.Ordinary income
Profit before tax−¥779m2022-01-01 → 2022-09-30Cons.Income before income taxes
Profit before tax−¥1.2bn2021-01-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)−¥795m2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥534m2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.2bn2021-01-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income−¥795m2022-01-01 → 2022-09-30Cons.Profit loss
Net income−¥1.2bn2021-01-01 → 2021-09-30Cons.Profit loss
Total assets¥4.5bnat 2022-09-30Cons.Assets
Total assets¥5.4bnat 2021-12-31Cons.Assets
Total assets¥4.2bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥604mat 2022-09-30Cons.Liabilities
Total liabilities¥1.1bnat 2021-12-31Cons.Liabilities
Net assets / equity¥3.9bnat 2022-09-30Cons.Net assets
Net assets / equity¥4.3bnat 2021-12-31Cons.Net assets
Net assets / equity¥3.5bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥3.7bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥3.8bnat 2021-12-31Cons.Cash and deposits
EPS (basic)¥-58.562022-01-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-31.922022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-42.12021-01-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-94.242021-01-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-31.682021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio86.5%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio79.3%at 2021-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio82.4%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 10
SegmentItemPeriodValue
jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥286m
jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥286m
jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥1.1bn
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥810m
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥810m
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2022-01-01 → 2022-09-30¥336m
jpcrp040300-q3r_E00987-000Drug Discovery Businessreportable segmentsegment profit2021-01-01 → 2021-09-30−¥1.4bn
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2021-01-01 → 2021-09-30¥637m
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2021-01-01 → 2021-09-30¥637m
jpcrp040300-q3r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2021-01-01 → 2021-09-30¥199m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 315
ItemContextValueUnit
Other noiPrior1YTDDuration813000JPY
Other noiCurrentYTDDuration3178000JPY
Non operating incomePrior1YTDDuration10345000JPY
Non operating incomeCurrentYTDDuration24660000JPY
Interest expenses noePrior1YTDDuration3081000JPY
Interest expenses noeCurrentYTDDuration4278000JPY
Guarantee commission noePrior1YTDDuration1087000JPY
Guarantee commission noeCurrentYTDDuration735000JPY
Stock issuance cost noePrior1YTDDuration2990000JPY
Stock issuance cost noeCurrentYTDDuration1434000JPY
Share acquisition rights issuance costs noePrior1YTDDuration5952000JPY
Share acquisition rights issuance costs noeCurrentYTDDuration－JPY
Other noePrior1YTDDuration30000JPY
Other noeCurrentYTDDuration49000JPY
Non operating expensesPrior1YTDDuration13143000JPY
Non operating expensesCurrentYTDDuration6498000JPY
Ordinary incomePrior1YTDDuration-1171814000JPY
Ordinary incomeCurrentYTDDuration-735543000JPY
Impairment loss elPrior1YTDDuration6108000JPY
Impairment loss elCurrentYTDDuration43062000JPY
Extraordinary lossPrior1YTDDuration6108000JPY
Extraordinary lossCurrentYTDDuration43062000JPY
Income before income taxesPrior1YTDDuration-1177923000JPY
Income before income taxesCurrentYTDDuration-778606000JPY
Income taxes currentPrior1YTDDuration5924000JPY
Income taxes currentCurrentYTDDuration16703000JPY
Income taxes deferredPrior1YTDDuration-5772000JPY
Income taxes deferredCurrentYTDDuration-91000JPY
Income taxesPrior1YTDDuration151000JPY
Income taxesCurrentYTDDuration16612000JPY
Profit lossPrior1YTDDuration-1178075000JPY
Profit lossCurrentYTDDuration-795218000JPY
Profit loss attributable to owners of parentPrior1YTDDuration-1178075000JPY
Profit loss attributable to owners of parentCurrentYTDDuration-795218000JPY
Profit lossPrior1YTDDuration-1178075000JPY
Profit lossCurrentYTDDuration-795218000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration-412000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration-1716000JPY
Deferred gains or losses on hedges net of tax ociPrior1YTDDuration4624000JPY
Deferred gains or losses on hedges net of tax ociCurrentYTDDuration30787000JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration11596000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration47369000JPY
Other comprehensive incomePrior1YTDDuration15809000JPY
Other comprehensive incomeCurrentYTDDuration76440000JPY
Comprehensive incomePrior1YTDDuration-1162265000JPY
Comprehensive incomeCurrentYTDDuration-718777000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration-1162265000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration-718777000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration－JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2021-12-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass